23andMe, FDA and DNA health profiling
Are companies that provide direct-to-consumer information on their personal genome -- including genetic susceptibility to disease -- creating new health risks that need to be regulated? On November 22 2013, the US Food and Drug Administration requested that the personalized DNA analysis company 23andMe "immediately discontinue marketing the PGS [Personal Genome Service] until such time as it receives FDA marketing authorization for the device". This week, Risk Bites looks at some of the questions raised by FDA's response to 23andMe's DNA Spit Test The Risk Bites Team: Producer: Andrew Maynard Research Director: David Faulkner Risk Bites is supported by: University of Michigan School of Public Health. http://www.sph.umich.edu/ University of Michigan Risk Science Center. http://umriskcenter.org RESOURCES 23andMe: http://23andme.com Letter from FDA to 23andMe: http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm David Dobbs: FDA Muzzles 23andMe After Talks Break Down http://daviddobbs.net/smoothpebbles/feds-muzzle-23andme-decide-public-best-be-ignorant-about-genetics/ TechCrunch: http://techcrunch.com/2013/11/25/23andme-fda-block/ Wall Street Journal: http://online.wsj.com/news/articles/SB10001424052702304281004579219893863966448 CNN: http://money.cnn.com/2013/11/25/technology/fda-23andme/ Risk Bites is your guide to making sense of risk. We cover everything from understanding and balancing the risks and benefits of everyday products, to health science more broadly, to the potential impacts of emerging technologies, to making sense of risk perception. If you enjoy our videos, please subscribe, and spread the word! Click here to see more videos: https://alugha.com/RiskBites